Brief: New Data From Phase 3 Trial Further Validate Prognostic Value Of Veracyte’S Decipher Prostate Genomic Classifier
04/10/2023 21:10
Oct 4 (Reuters) - Veracyte Inc VCYT.O :
* NEW DATA FROM PHASE 3 TRIAL FURTHER VALIDATE PROGNOSTIC
VALUE OF
VERACYTE’S DECIPHER PROSTATE GENOMIC CLASSIFIER
Source text for Eikon: ID:nBw2M9BdDa
Further company coverage: VCYT.O
((Reuters.briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina